Drug intelligence / Profile preview

Autologous Bone Marrow-Derived Mesenchymal Stem Cells (BM-MSCs)

Development stage: Unknown
Lead developer: Corestemchemon
Modality: Cell Therapies
Administration: Intrathecal, Intramuscular, Intradiscal

Overview

Autologous BM-MSCs are derived from a patient's own bone marrow and are used in cell therapy. They have **immunomodulatory, regenerative, and paracrine properties**, making them promising for treating various conditions, including degenerative diseases, chronic low back pain, and neurological disorders like ALS. Their mechanism involves modulating the immune response and promoting tissue repair.

Other names: Autologous Bone Marrow Mesenchymal Stem Cells

Beyond the preview

Go deeper on Autologous Bone Marrow-Derived Mesenchymal Stem Cells (BM-MSCs).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Autologous Bone Marrow-Derived Mesenchymal Stem Cells (BM-MSCs).

Explore the full profile